EXCLUSIVE: Plus Therapeutics Tells Benzinga 'As part of the agreement, Plus obtains a nonexclusive license and option for exclusivity for patients receiving CNS radiotherapy'
Portfolio Pulse from Benzinga Newsdesk
Plus Therapeutics has obtained a nonexclusive license and option for exclusivity for patients receiving CNS radiotherapy as part of an agreement.
September 08, 2023 | 10:30 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Plus Therapeutics' new agreement could potentially increase its market share in the CNS radiotherapy sector.
The agreement allows Plus Therapeutics to potentially increase its market share in the CNS radiotherapy sector. This could lead to increased revenues and profitability, which would likely have a positive impact on the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100